Memorial Sloan Kettering Cancer Center

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma | Globe Newswire | 10/9/2019

… 2020 October 08, 2019 08:00 ET Source: Salarius Pharmaceuticals HOUSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) – Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital (Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing Phase 1/2 clinical trial of Seclidemstat for …

Postdoctoral position – The Sarat Chandarlapaty Lab/Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center | Nature | 9/24/2019

New York, NY, United States Posted about 29 minutes ago Expires on November 23, 2019 Memorial Sloan Kettering Cancer Center ( MSK ) is one of the world’s premier cancer centers, committed to exceptional patient care, leading-edge research, and superb educational programs. The blending of research with patient care is at the heart of everything we do. The institution is a comprehensive cancer center whose purposes are the treatment and control …

Follow Memorial Sloan Kettering Cancer Center:    

MEMORIAL SLOAN KETTERING CANCER CENTER AMENITY KIT (Sodium Monofluorophosphate) Kit [ASP Global, LLc] | National Institutes of Health | 9/17/2019

RxNorm MEMORIAL SLOAN KETTERING CANCER CENTER AMENITY KIT- sodium monofluorophosphate Under Review - Editing is pending for RxNorm. If in scope, these drugs will include RxNorm normal forms when editing is complete. Get Label RSS Feed for this Drug MEMORIAL SLOAN KETTERING CANCER CENTER AMENITY KIT- sodium monofluorophosphate To receive this label RSS feed Copy the URL below and paste it into your RSS Reader application. To receive all DailyMed Updates …

Fate Therapeutics: Pioneer In iPSC Space Continues To Make Progress - Fate Therapeutics, Inc. (NASDAQ:FATE) | Seeking Alpha | 9/16/2019

… in mind that patients who are administered immunosuppressive drugs to treat acute GvHD have increased risk of cancer relapse and mortality (those who are refractory have mortality rates of over 70%). Fate’s collaboration with Memorial Sloan Kettering Cancer Center to advance off the shelf T-cell immunotherapies utilizing pluripotent cell lines (iPSC) was especially of interest. Expansion of the license agreement was an encouraging sign, whereby Fate gained access to …

Ezra Expands Its Full-Body Cancer Screening Service to California | PRWeb | 9/16/2019

Ezra Expands Its Full-Body Cancer Screening Service to California Share Article AI Healthcare Company Introduces its Technology to San Francisco and Los Angeles SAN FRANCISCO Ezra, the healthcare artificial intelligence (AI) company creating a new standard for early cancer detection, has announced the rollout of eight new MRI-based cancer screening locations in California, in partnership with RadNet, Inc. (NASDAQ: RDNT), the largest outpatient imaging network in the United …

ASTRO News: Adding Immunotherapy to Chemoradiation Decreases Local and Distant Recurrence of NSCLC | Memorial Sloan Kettering Cancer Center | 9/16/2019

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD , radiation oncologist …

Memorial Sloan Kettering Cancer Center oncologist receives lifetime achievement award | 9/15/2019

Memorial Sloan Kettering Cancer Center oncologist receives lifetime achievement award September 15, 2019 Add Topic To Email Alerts Please provide your email address to receive an email when new articles are posted on this topic . Submit Receive an email when new articles are posted on this topic . CLICK HERE TO SUBSCRIBE Click here to manage your alerts . Charles Rudin Charles Rudin, MD, PhD, received the Paul A. Bunn Jr. Scientific …

Patients with metastatic colorectal cancer harboring certain BRAF mutations may respond to anti-EGFR | 9/12/2019

… Research Authors: Senior author Hiromichi Ebi, MD, PhD, chief of the Division of Molecular Therapeutics at the Aichi Cancer Center Research Institute in Nagoya, Japan; and first author Rona Yaeger, MD , medical oncologist at Memorial Sloan Kettering Cancer Center Background: “Cancer genomic profiling is rapidly transforming the clinical management of cancer patients,” said Ebi. “Results from our study indicate that metastatic colorectal cancer patients with certain BRAF mutations should be …

CE TECH Supports the PaulieStrong Foundation to Help Fight Childhood Cancer | PRWeb | 9/12/2019

… will take place on Sept 23, 2019 at Scarsdale Golf Club in Hartsdale, N.Y. CE Tech will sponsor the event’s Helicopter Ball Drop —a supplemental fundraising activity aimed generating an additional $20K to support Memorial Sloan Kettering Cancer Center and their work fighting childhood cancer. For more information about sponsorship opportunities, visit PaulieStrong Get Involved . About CE TECH Headquartered in Warren, NJ, CE Tech, (Cutting Edge Technologies), is an IT …

The American Journal of Managed Care® Announces the Institute for Value-Based Medicine® VB-Onc™ Meeting in Nashville | Business Wire | 9/11/2019

CRANBURY, N.J.- The American Journal of Managed Care ® ( AJMC ®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, with its Institute for Value-Based Medicine® will host a regional VB-Onc™ meeting that will provide an overview of the direction of oncology value-based care. The meeting will take place Thursday, Oct. 24, 5:30-8:45 p.m. at Hutton Hotel in Nashville, Tennessee, and will be co-chaired by …

The American Journal of Managed Care® Announces the Institute for Value-Based Medicine® VB-Onc™ Meeting in Nashville | Business & Finance | heraldchronicle.com | Business Wire | 9/11/2019

CRANBURY, N.J.–(BUSINESS WIRE)–Sep 11, 2019– The American Journal of Managed Care ® ( AJMC ®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, with its Institute for Value-Based Medicine® will host a regional VB-Onc™ meeting that will provide an overview of the direction of oncology value-based care. The meeting will take place Thursday, Oct. 24, 5:30-8:45 p.m. at Hutton Hotel in Nashville, Tennessee, and …

Speaker: Rationale exists to test CAR T-cell therapy in KRAS-mutated lung cancer | 9/11/2019

BARCELONA — Enriched cell surface expression of mesothelin in KRAS -mutated adenocarcinoma and supporting preclinical evidence suggest chimeric antigen receptor T-cell therapy targeting mesothelin may be feasible and efficacious for this group of patients, according to a presentation at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “ KRAS mutation is the most common oncogenic driver mutation in lung adenocarcinoma and is associated with poor prognosis …

Varian-Equipped New York Proton Therapy Center Treats First Patients | 9/11/2019

Company Website Share: PALO ALTO, Calif., Sept. 10, 2019 /PRNewswire/ – The New York Proton Center (NYPC) has treated its first proton therapy cancer patients. Equipped with the Varian ProBeam® proton therapy system, NYPC is New York State’s first proton therapy facility and is a collaboration between Memorial Sloan Kettering Cancer Center, Montefiore Health System, and Mount Sinai Health System. NYPC is expected to treat 1,400 patients annually, including most children …

Assistant or Associate Attending – Molecular Diagnostics Service, Department of Pathology | GenomeWeb | 9/11/2019

Memorial Sloan Kettering Cancer Center (MSK) is one of the world’s premier cancer centers, committed to exceptional patient care, leading-edge research, and superb educational programs. The blending …

Study Published by Clinical Cancer Research Shows PGDx’s Liquid Biopsy Predictive of PD-1 Blockade Response | Business Wire | 9/10/2019

BALTIMORE–(BUSINESS WIRE)–Sep 10, 2019– A study published by Clinical Cancer Research , a journal of the American Association for Cancer Research (AACR), shows Personal Genome Diagnostics Inc.’s (PGDx) liquid biopsy technology successfully detected microsatellite instability (MSI) in circulating tumor DNA (ctDNA), and was able to estimate the likelihood of both an immediate and durable response to immune checkpoint blockade in cancer patients with MSI. The study results point …

Why Bravo TV’s Real Housewives of Atlanta Star, Tanya Sam Launched The Ambition Fund For Minority Entrepreneurs | Forbes | 9/10/2019

Tanya Sam Tanya Sam You’ve might’ve seen Tanya Sam’s sparkling smile and vibrant personality appear on Bravo TV’s The Real Housewives of Atlanta on any given Sunday night but Sam is also widely known as a tech-savvy investor that’s dedicated to empowering Atlanta’s next generation of minority entrepreneurs. Prior to joining the technology industry, Sam served as an Oncology nurse practitioner at Northside Hospital, New York-Presbyterian Hospital, Memorial …

Blood Cancer Experts Discuss Latest Treatment Innovations at NCCN 2019 Annual Congress: Hematologic Malignancies(tm) | 9/10/2019

… the National Comprehensive Cancer Network ® ( NCCN ® ), and co-chaired by Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma , Stanford University School of Medicine and Andrew D. Zelenetz, MD, PhD , Medical Director, Quality Informatics , Memorial Sloan Kettering Cancer Center . The Congress will address new, emerging, and novel therapeutic agents, diagnostics, and other advances in the management of blood cancers. The sessions will also explore the growing role of immunotherapies, biosimilars …

Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer | Markets Insider | Business Insider | 9/10/2019

Late-breaking results presented for U3-1402, a HER3 targeting ADC, in patients with metastatic EGFR mutated, TKI resistant NSCLC - Manageable safety profile reported for U3-1402 with six confirmed partial responses and a reduction in tumor size in 22 of 26 evaluable patients across all doses - Partial responses and tumor shrinkage observed in patients with diverse mechanisms of resistance - Study to advance into dose expansion including additional cohort of patients with …

Blood Cancer Experts Discuss Latest Treatment Innovations at NCCN 2019 Annual Congress: Hematologic Malignancies™ | PR Newswire | 9/10/2019

… the National Comprehensive Cancer Network® ( NCCN ®), and co-chaired by Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University School of Medicine and Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center . The Congress will address new, emerging, and novel therapeutic agents, diagnostics, and other advances in the management of blood cancers. The sessions will also explore the growing role of immunotherapies, biosimilars …

Another study shows liquid biopsy can detect cancer immunotherapy biomarker | MedCity News | 9/10/2019

… to the first drug to win a so-called tissue-agnostic cancer approval from the Food and Drug Administration. Researchers from Baltimore-based liquid biopsy maker Personal Genome Diagnostics, Johns Hopkins University, New York’s Memorial Sloan Kettering Cancer Center and other institutions found that PGDx’s product was able to detect microsatellite instability, or MSI, in circulating tumor DNA and also to estimate the likelihood of an immediate and durable response …

National Cancer Institute

Modern Healthcare Selects Dr. Andrew Pecora, Outcomes Matter Innovations CEO, as One of its “50 Most Influential Clinical Executives in America” | Markets Insider | Business Insider | 6/27/2019

Memorial Sloan Kettering Cancer Center and Georgetown Lombardi Cancer Center. Dr. Pecora created and expanded the John Theurer Cancer Center, which under his guidance, was approved by the National Cancer Institute to become a member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center Consortium – one of just 16 NCI-designated cancer consortia. About Outcomes Matter Innovations A healthcare transformation company with multiple diversified interests in the healthcare arena, Outcomes …

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | Markets Insider | Business Insider | 5/30/2019

… remarkable power of the human cell.” Funding sources will include the government – grants from the National Institutes of Health, the National Cancer Institute, for example – individual and corporate philanthropy, venture philanthropy and venture capital. Hackensack … Cancer Consortium. Hackensack Meridian Health has formed a partnership with Memorial Sloan Kettering Cancer Center to create an exceptional uniform standard of care throughout the network’s acute care hospitals and expansive outpatient network. The center …

AMA

Guidelines say more women may need breast cancer gene test | NBC News | 8/20/2019

… influential health group recommended Tuesday. At issue are genes called BRCA1 and BRCA2 . When they’re mutated, the body can’t repair damaged DNA as well, greatly increasing the chances of breast, ovarian and certain other cancers … Domchek of the University of Pennsylvania and Mark Robson of Memorial Sloan Kettering Cancer Center, who weren’t involved with the new guidelines, wrote in an editorial accompanying them. But too few high-risk women ever …

Food and Drug Administration

Ezra Expands Its Full-Body Cancer Screening Service to California | PRWeb | 9/16/2019

… Dr. Siddhartha Mukherjee - Pulitzer Prize winning author of “The Emperor Of All Maladies”, Dr. Joseph Alukal, Dr. Oguz Akin from Memorial Sloan Kettering Cancer Center, Dr. Lawrence N. Tanenbaum of RadNet, Inc., Dr. John Melnick … device that has not yet received marketing authorization from the Food and Drug Administration (“FDA”). The safety and effectiveness of the device have not yet been established. After further study of our technology, we plan …

Another study shows liquid biopsy can detect cancer immunotherapy biomarker | MedCity News | 9/10/2019

Food and Drug Administration. Researchers from Baltimore-based liquid biopsy maker Personal Genome Diagnostics, Johns Hopkins University, New York’s Memorial Sloan Kettering Cancer Center and other institutions found that PGDx’s product was able to detect microsatellite instability, or MSI, in circulating tumor DNA and also to estimate the likelihood of an immediate and durable response to treatment with an immune checkpoint inhibitor. Merck & Co.’s PD-1 inhibitor Keytruda (pembrolizumab …

National Institutes of Health

More Than 5 Million Cancer Survivors Experience Chronic Pain, Twice the Rate of the General Population | PRWeb | 6/21/2019

… pain in cancer survivors can help inform future health care educational priorities and policies. Researchers from the American Cancer Society, Memorial Sloan Kettering Cancer Center, and the University of Virginia were part of the study … Report’s “Honor Roll” Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index …

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | Markets Insider | Business Insider | 5/30/2019

… translational science by leveraging the remarkable power of the human cell.” Funding sources will include the government – grants from the National Institutes of Health, the National Cancer Institute, for example – individual and corporate philanthropy, venture … Cancer Consortium. Hackensack Meridian Health has formed a partnership with Memorial Sloan Kettering Cancer Center to create an exceptional uniform standard of care throughout the network’s acute care hospitals and expansive outpatient network. The center …

Biotech

Health Care Sector Update for 07/22/2019: KZIA,DVA,FGEN,DVA,NTEC - Nasdaq.com | 7/22/2019

Biotechnology index was climbing almost 0.4%. Among health care stocks moving on news: (+) Kazia Therapeutics Ltd ( KZIA ) rose more than 13% after the Australian company said the Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of a combination of radiotherapy and the company’s GDC-0084 drug candidate during a phase I clinical trial in patients whose cancer has spread to their brains. The first part …

White House Yanks Drug ‘Rebate’ Plan to Lower Costs for Some | U.S. News & World Report | 7/11/2019

… This is a big setback,” said Peter Bach, director of the Center for Health Policy and Outcomes at New York’s Memorial Sloan Kettering Cancer Center. The rebate rule “was not good policy (since) it would … for the medicines they need,” Jim Greenwood, head of the Biotechnology Innovation Organization, said in a statement. Shares of pharmaceutical companies dropped Thursday but drug store chains and insurers gained. Drugmaker Merck & Co. dropped 4.5 …

American Society of Clinical Oncology

Babak Baseri M.D. M.S., Joins The Oncology Institute of Hope and Innovation | PRWeb | 8/15/2019

… his medical school residency and fellowship, he trained at numerous healthcare systems serving diverse patient populations including the nationally recognized Memorial Sloan Kettering Cancer Center in New York, Hackensack University Medical Center in New Jersey … outcomes. He is fluent in English and Farsi. Professional Memberships American Society of Clinical Oncology (ASCO) American Society of Hematology (ASH) Member of American College of Physicians (ACP) Journal of American Medical Association (JAMA) Alpha …

A New Breast Cancer Treatment Can Extend the Lives of Younger Patients, Study Finds | Yahoo News | 6/5/2019

… to standard hormone therapy, a clinical trial has found. Data presented by the drugmaker Novartis this week at the annual American Society of Clinical Oncology (ASCO) Meeting showed that after about three and a half … Norton, MD, medical director of the Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York City, said the new findings were exciting. “My expectation is that, when faced with these data, it’ll …

Clinical Data

Verastem unveils Copiktra data in peripheral T-cell lymphoma - Verastem, Inc. (NASDAQ:VSTM) | Seeking Alpha | 6/21/2019

Verastem (NASDAQ: VSTM ) +3.8% pre-market after presenting supportive Phase 1 clinical data for duvelisib (Copiktra) in patients with relapsed or refractory peripheral T-cell lymphoma at International Conference on Malignant Lymphoma currently underway in Switzerland. “Patients with relapsed or refractory PTCL who were treated with duvelisib demonstrated preliminary but compelling clinical activity,” says Steven Horwitz of Memorial Sloan Kettering Cancer Center, co-principal investigator of the Phase 1 and …

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma | Business & Finance | manchestertimes.com | Business Wire | 6/21/2019

… to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib (COPIKTRA™) in patients with relapsed or refractory peripheral T-cell lymphoma … demonstrated preliminary, but compelling clinical activity,” said Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, co-principal investigator of the Phase 1 and 2 studies, and lead author of the oral presentation. “Although the patient …

ACA

ENT and Allergy Associates Expands its Westchester County Clinical Presence | Globe Newswire | 8/7/2019

… Otolaryngology Head & Neck surgery at the Manhattan Eye, Ear & Throat Hospital and the New York Presbyterian Hospital including training at Memorial Sloan Kettering Cancer Center. In addition, he completed his fellowship in Laryngology: Voice and … Top Doctor”, graduated magna cum laude from Cornell University in Ithaca, NY. He then went on to obtain his medical degree at the Weill Medical College of Cornell University, and successfully completed his joint residency …

Jennifer Aviado-Langer, DNP, FNP is recognized by Continental Who’s Who | PR Newswire | 7/17/2019

… Who for her outstanding contributions in the medical field as a Doctor of Nursing Practice and Family Nurse Practitioner at Memorial Sloan Kettering Cancer Center. Continue Reading (PRNewsfoto/Continental Who’s Who) Excelling at expert, caring … Monmouth University . Dr. Aviado-Langer is certified by the American Academy of Nurse Practitioners (AANP) in Family Health and by the American Nurses Credentialing Center (ANCC) in Medical-Surgical. To further her professional development, Dr …

Precision Medicine

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center | PR Newswire | 7/22/2019

… July 22, Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA ), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use … approach to clinical research that is sometimes referred to as ‘precision medicine’ or ‘personalized medicine’, in which treatments are carefully targeted to those patients most likely to benefit. It is expected that the trial will …

Managing Breast Cancer in 2015 - The ASCO Post | 5/10/2019

… breast cancer expert and ASCO past president Larry Norton, MD , Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York. Reinvention of Clinical Trials Please tell the … potential reinvention of clinical trials due to the advent of precision medicine: that is, defining a particular target, developing an intervention to hit that target, and then examining the results. Seeing responses in this setting …

Integrative Medicine

Advancing the Science and Art of Integrative Oncology - The ASCO Post | 5/25/2019

Advancing the Science and Art of By Jun J. Mao, MD, MSCE February 10, 2019 Advertisement Jun J. Mao, MD, MSCE In 2019 , we will mark the 20th year of the establishment of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center (MSK), which helped lay the foundation for the emerging field of integrative oncology. Over the past 2 decades, academic cancer institutions, including The University of Texas MD …

Addressing Patient Expectations Regarding the Use of Alternative Therapies - The ASCO Post | 5/25/2019

Addressing Patient Expectations Regarding the Use of Alternative Therapies By Shelly Latte-Naor, MD, and Jun J. Mao, MD, MSCE December 10, 2018 Advertisement is guest edited by Jun J. Mao, MD, MSCE , Laurance S. Rockefeller Chair in Integrative Medicine and Chief, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York. GUEST EDITOR Jun J. Mao, MD, MSCE The ASCO Post’s series is intended to facilitate the availability of …

Novartis

Roche’s combo lymphoma treatment wins FDA’s accelerated approval | Yahoo News | 6/10/2019

Novartis AG, is also approved for patients with advanced DLBCL. Dr. Matthew Matasar, a hematologist at New York’s Memorial Sloan Kettering Cancer Center who was involved in the development of Polivy, said the drug could be an option for some patients to try before determining whether they need to move on to CAR-T treatments. He said Polivy can only be used once due to the risk of serious neurotoxicity …

A New Breast Cancer Treatment Can Extend the Lives of Younger Patients, Study Finds | Yahoo News | 6/5/2019

… breast cancer when given in addition to standard hormone therapy, a clinical trial has found. Data presented by the drugmaker Novartis this week at the annual American Society of Clinical Oncology (ASCO) Meeting showed that … Norton, MD, medical director of the Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York City, said the new findings were exciting. “My expectation is that, when faced with these data, it’ll …

Merck

SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study | Nasdaq | 7/31/2019

… Phase 1/2 Basket Study By GlobeNewswire, July 31, 2019, 08:15:00 AM EDT A A A - Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian … Assistant Attending Physician in Gynecologic Medical Oncology Service at the Memorial Sloan Kettering Cancer Center (MSKCC), are serving as co-principal investigators for this study. About the StudyThe Phase 1/2 open-label, multicenter, multi-arm …

UPDATE 1-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study | Yahoo News | 6/3/2019

Adds comments from AstraZeneca executive, PIX available) By Julie Steenhuysen CHICAGO, June 2 (Reuters) - AstraZeneca and Merck & Co’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long … positive,” said Dr. Eileen O’Reilly, a pancreatic cancer expert at Memorial Sloan Kettering Cancer Center in New York, who helped lead the study. O’Reilly said the findings reinforce new guidelines from the National Comprehensive Cancer …

Celgene

ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads | FierceBiotech | 5/31/2019

Memorial Sloan Kettering Cancer Center, has shown glimpses of promise in a hard-to-treat form of lung cancer and will be posting updated data at ASCO this coming week. Celgene/BMS Celgene, in the middle of being subsumed by Bristol-Myers Squibb, also has new data out from a next-gen CAR-T. JCAR-017 (bought from its $9 billion deal with biotech Juno last year), is being tested …

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | PR Newswire | 5/30/2019

… through his clinical trials showing this medication halts the progression of the disease. Sol J. Barer , Ph.D., the founder of Celgene and chair of the Board of Directors of Teva Pharmaceuticals, will serve as founding … Cancer Consortium. Hackensack Meridian Health has formed a partnership with Memorial Sloan Kettering Cancer Center to create an exceptional uniform standard of care throughout the network’s acute care hospitals and expansive outpatient network. The center …

Pfizer

Lynparza stalls pancreatic cancer in patients with BRCA mutations -study | Yahoo News | 6/2/2019

… these inherited mutations, the finding is significant. “This was clearly positive,” said Dr. Eileen O’Reilly, a pancreatic cancer expert at Memorial Sloan Kettering Cancer Center in New York, who helped lead the study. O’Reilly said … rival PARP inhibitors Rubraca from Clovis Oncology, GSK’s Zejula and Pfizer’s talazoparib. (Reporting by Julie Steenhuysen; additional reporting by Ludwig Burger in Frankfurt; editing by Bill Berkrot …

Pfizer & Merck’s Inlyta Combo Becomes First FDA-Approved Anti-PD-L1 Therapy For Kidney Cancer - PharmaVOICE : PharmaVOICE | 5/15/2019

… the treatment of advanced renal cell carcinoma (RCC). The decision was announced by the drug’s co-developers Merck KGaA and Pfizer, and marks the first FDA approval for an anti-PD-L1 therapy as part … Jack and Dorothy Byrne Chair in Clinical Oncology at the Memorial Sloan Kettering Cancer Center in New York, and principal investigator on the trial. “With today’s FDA approval of avelumab in combination with axitinib, we …

Genentech

Lymphoma Research Foundation to Honor Leading Lymphoma Expert Anas Younes, MD at 2019 Annual Gala on September 26 | PRWeb | 7/23/2019

… of Renowned Lymphoma Expert During National Blood Cancer Awareness Month 2019 LRF Gala Distinguished Leadership Award recipient, Anas Younes, MD (Memorial Sloan Kettering Cancer Center) The Foundation is critical to helping advance research and improved … patients through education.” The Lymphoma Research Foundation will also honor Genentech with this year’s Corporate Leadership Award in recognition of being pioneers in drug development, improving patient outcomes and nearly a decade of supporting the …

ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads | FierceBiotech | 5/31/2019

… next-gen treatments, namely California biotech Atara Biotherapeutics’ work on mesothelin-targeted CAR-T. This therapy, being researched with the Memorial Sloan Kettering Cancer Center, has shown glimpses of promise in a hard-to-treat … in the oncology and hematology global clinical development teams at Genentech. Berger arrives at a time when Reed, who joined Sanofi in July 2018, is starting to reshape the R&D group in line with …

Bristol-Myers Squibb

Drs. Joshua Bauml, Wei-Chu Victoria Lai, and Aaron Lisberg receive prestigious LUNGevity 2019 Career Development Awards | PR Newswire | 8/15/2019

… treatment in enhancing the immune response in patients with advanced non-small cell lung cancer. Wei-Chu Victoria Lai , MD, Memorial Sloan Kettering Cancer Center, Overcoming chemoresistance through epigenetic modifications in SCLC . Dr. Lai’s laboratory … Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, the Schmidt Legacy Foundation, and individual donors. About LUNGevity Foundation LUNGevity is the nation’s …

ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads | FierceBiotech | 5/31/2019

Memorial Sloan Kettering Cancer Center, has shown glimpses of promise in a hard-to-treat form of lung cancer and will be posting updated data at ASCO this coming week. Celgene/BMS Celgene, in the middle of being subsumed by Bristol-Myers Squibb, also has new data out from a next-gen CAR-T. JCAR-017 (bought from its $9 billion deal with biotech Juno last year), is being tested …

Bristol-Myers

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Dunkel 3 , Audra K Miller 6 , 7 , Pranav R Santapuram 8 , David H Abramson 1 , 2 1 Ophthalmic Oncology Service , Memorial Sloan Kettering Cancer Center , New York City , New York , USA 2 Department of Ophthalmology … Apexigen, personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Eisai, personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted …

Drs. Joshua Bauml, Wei-Chu Victoria Lai, and Aaron Lisberg receive prestigious LUNGevity 2019 Career Development Awards | PR Newswire | 8/15/2019

… treatment in enhancing the immune response in patients with advanced non-small cell lung cancer. Wei-Chu Victoria Lai , MD, Memorial Sloan Kettering Cancer Center, Overcoming chemoresistance through epigenetic modifications in SCLC . Dr. Lai’s laboratory … Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, the Schmidt Legacy Foundation, and individual donors. About LUNGevity Foundation LUNGevity is the nation’s …

Weill Cornell Medicine

The Gray Foundation Announces $25 Million in New Team Science Funding for BRCA-Related Cancer Research - Yahoo Finance | Yahoo News | 7/23/2019

… S. Brugge, PhD – Ludwig Center at Harvard; Harvard Medical School Lewis C. Cantley, PhD – Sandra and Edward Meyer Cancer Center; Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center Leif W. Ellisen, MD, PhD … British Columbia, Brigham and Women’s Hospital, Stanford University, QIMR Berghofer, Memorial Sloan Kettering Cancer Center and University. Chi Van Dang, M.D., Ph.D., world-renowned medical oncologist and Chief Science Advisor for the Gray Foundation, oversaw …

Lymphoma Research Foundation Announces Andrew D. Zelenetz, MD, PhD as Scientific Advisory Board Chair | PRWeb | 7/1/2019

… a comprehensive series of education programs, outreach initiatives and patient services – is proud to welcome Andrew D. Zelenetz, MD, PhD (Memorial Sloan Kettering Cancer Center) as Chair of its industry leading Scientific Advisory Board (SAB … James Cerhan, MD (Mayo Clinic, Rochester) and Peter Martin, MD (Weill Cornell Medicine). In addition to their charge of reviewing grant proposals and making recommendations regarding research priorities and funding to the Foundation’s Board of …

Fate Therapeutics

Fate Therapeutics: Pioneer In iPSC Space Continues To Make Progress - Fate Therapeutics, Inc. (NASDAQ:FATE) | Seeking Alpha | 9/16/2019

Shares of Fate Therapeutics ( FATE ) have risen by 475% since my Jan 2017 article stated that the stock was set to gain momentum. I’ve re-recommended a position here on several occasions since, as the … refractory have mortality rates of over 70%). Fate’s collaboration with Memorial Sloan Kettering Cancer Center to advance off the shelf T-cell immunotherapies utilizing pluripotent cell lines (iPSC) was especially of interest. Expansion of the …

Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells | Globe Newswire | 8/14/2019

… T Cells Expressing a Chimeric Antigen Receptor that are Derived from Pluripotent Stem Cells August 14, 2019 08:00 ET Source: Fate Therapeutics, Inc. SAN DIEGO, Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company … The foundational patent, which expires in 2034, is owned by Memorial Sloan Kettering Cancer Center (MSK) and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. “The breadth of this newly-issued patent …

MedImmune

AstraZeneca hires R&D executive to lead breast cancer research, $7B Daiichi drug pact | FierceMedicalDevices | 5/16/2019

… paid by pharma companies for work but had not been disclosing it properly. He had been physician-in-chief at Memorial Sloan Kettering Cancer Center, but was forced out last fall over the allegations—something … of Bahija Jallal, Ph.D., former head of its biologics arm MedImmune, now CEO of Immunocore, as well as portfolio strategy chief Mark Mallon. RELATED: AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer …

AstraZeneca hires R&D executive to lead breast cancer research, $7B Daiichi drug pact | FierceBiotech | 5/16/2019

… paid by pharma companies for work but had not been disclosing it properly. He had been physician-in-chief at Memorial Sloan Kettering Cancer Center, but was forced out last fall over the allegations—something … of Bahija Jallal, Ph.D., former head of its biologics arm MedImmune, now CEO of Immunocore, as well as portfolio strategy chief Mark Mallon. RELATED: AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer …

Spring Mountain Capital

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer | PR Newswire | 12/14/2017

Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email [email protected] . View original content with multimedia: http://www.prnewswire.com/news-releases/ucla-and-caltech …

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments | PR Newswire | 12/14/2017

Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email . View original content with multimedia: http://www.prnewswire.com/news-releases/ucla-and-caltech-study-uses …

Sound Ventures

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer | PR Newswire | 12/14/2017

Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email [email protected] . View original content with multimedia: http://www.prnewswire.com/news-releases/ucla-and-caltech …

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments | PR Newswire | 12/14/2017

Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email . View original content with multimedia: http://www.prnewswire.com/news-releases/ucla-and-caltech-study-uses …

Leukemia & Lymphoma Society

Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial | Nasdaq | 6/7/2019

… relapsed/refractory mantle cell lymphoma (“r/r MCL”) or relapsed/refractory diffuse large B-cell lymphoma (“r/r DLBCL”) at Memorial Sloan Kettering Cancer Center (MSK). This trial will enroll approximately 40 patients to assess … common aggressive non-Hodgkin’s lymphoma (NHL) subtype according to the Leukemia & Lymphoma Society (LLS). Researchers at MSK have shown preclinical data demonstrating that dual targeting of Bruton’s tyrosine kinase (BTK) in the BCR pathway with …

MD Anderson Cancer Center

Mayo Clinic nabs top spot (again) in U.S. News best hospital rankings | Healthcare Dive | 7/30/2019

MD Anderson Cancer Center in cancer, and Memorial Sloan Kettering Cancer Center in gynecology. The magazine also evaluates hospitals’ performance on nine common procedures and conditions, such as heart bypass surgery, colon cancer surgery and hip replacement. A total of 57 hospitals were rated high performing in all nine procedures and conditions, while 1,447 received a high-performing rating in at least one of nine. Another prominent hospital quality-rating …

NY hospitals rise in ‘U.S. News’ rankings under new methodology | Crain’s New York Business | 7/30/2019

Memorial Sloan Kettering Cancer Center held on to the No. 2 spot behind MD Anderson Cancer Center in Houston. Hospital for Special Surgery maintained its status as the top-ranked hospital for orthopedics. The U.S. News rankings have been criticized in the past for placing too heavy a weighting on reputation through its use of physician surveys. But the list is undoubtedly a key marketing tool for area hospitals, which …

University of Texas MD Anderson Cancer Center

Mayo Clinic nabs top spot (again) in U.S. News best hospital rankings | Healthcare Dive | 7/30/2019

University of Texas MD Anderson Cancer Center in cancer, and Memorial Sloan Kettering Cancer Center in gynecology. The magazine also evaluates hospitals’ performance on nine common procedures and conditions, such as heart bypass surgery, colon cancer surgery and hip replacement. A total of 57 hospitals were rated high performing in all nine procedures and conditions, while 1,447 received a high-performing rating in at least one of nine. Another prominent …

U.S. News Releases 2019-2020 Top Hospitals List | WebMD | 7/30/2019

Top Five for Cardiology and Heart Surgery 1. Cleveland Clinic, Ohio 2. Mayo Clinic, Rochester, MN 3. Cedars-Sinai Medical Center, Los Angeles 4. New York-Presbyterian Hospital/Columbia and Cornell, New York City 5. Massachusetts General Hospital, Boston Top Five for Cancer 1. University of Texas MD Anderson Cancer Center, Houston 2. Memorial Sloan Kettering Cancer Center, New York City 3. Mayo Clinic, Rochester, MN 4. Johns Hopkins Hospital …

Mayo Clinic

Ruth Bader Ginsburg underwent treatment for tumor on pancreas, Supreme Court says | NBC News | 8/23/2019

… tumor on her pancreas, the high court said in a statement Friday. The three-week radiation treatment, performed at the Memorial Sloan Kettering Cancer Center in New York City, was administered after doctors discovered a … care,” said Dr. Kenneth Merrell, a radiation oncologist at the Mayo Clinic in Rochester, Minnesota. Merrell has not treated Justice Ginsberg. “We are finding that this is a very tolerable course of treatment with little …

How do you get providers to comply with patient record requests? This group launched star ratings | FierceHealthcare | 8/21/2019

Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford Health Care and Northwest Memorial Hospital all received one star on their scorecard. The hospitals did not respond to a request for comment. FierceHealthcare will update this story with comments by organization officials when they respond. According to Ciitizen, HIPAA-compliant components include accepting requests by email or fax, sending records in the format requested and to the requested designee, sending records …

Massachusetts General Hospital

Blood Cancer Experts Discuss Latest Treatment Innovations at NCCN 2019 Annual Congress: Hematologic Malignancies™ | PR Newswire | 9/10/2019

… Saul Rosenberg Professor of Lymphoma , Stanford University School of Medicine and Andrew D. Zelenetz , MD, PhD , Medical Director, Quality Informatics , Memorial Sloan Kettering Cancer Center . The Congress will address new, emerging, and novel therapeutic agents … Square, and features the following faculty: Jeremy S. Abramson , MD , Massachusetts General Hospital Cancer Center Muhamed Baljevic , MD , University of Nebraska Medical Center , Fred & Pamela Buffett Cancer Center Rafael Bejar , MD, PhD , UC San Diego …

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN | PR Newswire | 8/19/2019

… Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women’s Cancer Center Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer … Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

Cleveland Clinic

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN | PR Newswire | 8/19/2019

… Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA … Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

Mayo Clinic nabs top spot (again) in U.S. News best hospital rankings | Healthcare Dive | 7/30/2019

Cleveland Clinic for cardiology and heart surgery, University of Texas MD Anderson Cancer Center in cancer, and Memorial Sloan Kettering Cancer Center in gynecology. The magazine also evaluates hospitals’ performance on nine common procedures and conditions, such as heart bypass surgery, colon cancer surgery and hip replacement. A total of 57 hospitals were rated high performing in all nine procedures and conditions, while 1,447 received a high-performing rating in …

HCA

How do you get providers to comply with patient record requests? This group launched star ratings | FierceHealthcare | 8/21/2019

RELATED: Editor’s Corner—I write about healthcare. I still found myself lost in the unnavigable healthcare system “A significant strategy in improving quality involves measuring and publicly reporting on provider performance - by specific provider,” McGraw … also some of the biggest names in healthcare. Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford Health Care and Northwest Memorial Hospital all received one star on their scorecard. The hospitals did not respond to …

New Doctor Specializing in Latest Microsurgical Techniques Joins NJ Practice | Markets Insider | Business Insider | 7/24/2019

… He returned to the University of Pennsylvania for residency. Then, completed his training with a reconstructive microsurgery fellowship program at Memorial Sloan Kettering Cancer Center in New York City where he performed over 200 free … in Edison . He will also be on staff at CentraState Healthcare in Freehold , Capital Health Medical Center in Hopewell , and Atlantic Health’s Overlook Medical Center in Summit . For more information on the practice or to …

Moffitt Cancer Center

NCCN Advances Cancer Research and Oncology Career Development with Young Investigator Awards, Poster Presentations, and Fellows Program | PR Newswire | 5/8/2019

… Lurie Comprehensive Cancer Center of Northwestern University , Genomic Determinants of Responses to Immunotherapy in Merkel Cell Carcinoma Kedar Kirtane MD, Moffitt Cancer Center , Feasibility of a Digitized Peer-to-Peer Patient Support System for Patients … Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

National Comprehensive Cancer Network Working with Health Officials in Bolivia to Improve Cancer Care | PR Newswire | 4/24/2019

Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford …

Barnes-Jewish Hospital

NCCN Advances Cancer Research and Oncology Career Development with Young Investigator Awards, Poster Presentations, and Fellows Program | PR Newswire | 5/8/2019

Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH ; O’Neal Comprehensive Cancer Center at UAB, Birmingham, AL ; Roswell Park Comprehensive Cancer Center, Buffalo, NY ; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO ; St. Jude Children’s Research Hospital/The University of Tennessee Health …

National Comprehensive Cancer Network Working with Health Officials in Bolivia to Improve Cancer Care | PR Newswire | 4/24/2019

Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford …

Fred Hutchinson Cancer Research Center, Seattle WA

NCCN and AstraZeneca Support Quality Improvements for Lung Cancer Care | PR Newswire | 5/31/2019

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, MD ; Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, IL ; Mayo Clinic Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy - The ASCO Post | 5/10/2019

Memorial Sloan Kettering Cancer Center, where phase I clinical trials are currently underway. JCAR015 is currently being tested in clinical trials at Seattle Children’s Hospital for relapsed/refractory CD19-positive pediatric leukemia and at Fred Hutchinson Cancer Research Center for refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute lymphoblastic leukemia. Data on these programs will be presented at the 54th Annual Meeting of the American Society of Hematology meeting …

Seattle Cancer Care Alliance, Seattle WA

NCCN and AstraZeneca Support Quality Improvements for Lung Cancer Care | PR Newswire | 5/31/2019

Seattle Cancer Care Alliance, Seattle, WA ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, MD ; Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, IL ; Mayo Clinic Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH ; O’Neal …

National Comprehensive Cancer Network Working with Health Officials in Bolivia to Improve Cancer Care | PR Newswire | 4/24/2019

Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell …

Health Net

Hackensack Meridian Health Announces Leadership at New Center for Discovery and Innovation | Markets Insider | Business Insider | 5/6/2019

EDISON, N.J. , May 6, 2019 /PRNewswire/ – Hackensack Meridian Health, New Jersey’s largest and most comprehensive and integrated health network, announced the appointments of Sol J. Barer , Ph.D., as chair of the Board of Directors and … campus in Nutley and Clifton . Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer …

Many Pelvic Tumors in Women May Have Common Origin - Fallopian Tubes | PR Newswire | 10/17/2017

Health Network in Toronto ; Michael Considine , Leslie Cope , Robert Kurman and le- Ming Shih of Johns Hopkins Medical Institutions in Baltimore ; and Robert Soslow of Memorial Sloan Kettering Cancer Center in New York . Funding for the study was provided by Arnold Chavkin and Laura Chang , the Chia Family Foundation, Department of Defense CDMRP Grant W81XWH-11-2-0230, and National Cancer Institute grant P30CA008748. Contact: Gregory Williams , 212-404-3500, View original content with …

Meridian Health Plan

JFK Health Joins Hackensack Meridian Health and Expands New Jersey’s Most Comprehensive and Integrated Health Care Network to 16 Hospitals | PR Newswire | 1/3/2018

Memorial Sloan Kettering Cancer Center offering a new standard of cancer care available to people across the state. Additionally, a campus in Plainfield features a satellite emergency department open 24-7, dialysis treatment and other services. The two networks are aligned in advancing education for the next generation of health care providers. Later this year, Hackensack Meridian Health plans to open a medical school with Seton Hall University . Meanwhile, JFK has …

JFK Health Joins Hackensack Meridian Health and Expands New Jersey’s Most Comprehensive and | PR Newswire | 1/3/2018

Memorial Sloan Kettering Cancer Center offering a new standard of cancer care available to people across the state. Additionally, a campus in Plainfield features a satellite emergency department open 24-7, dialysis treatment and other services. The two networks are aligned in advancing education for the next generation of health care providers. Later this year, Hackensack Meridian Health plans to open a medical school with Seton Hall University . Meanwhile, JFK has …

Fred Hutchinson

NCCN and AstraZeneca Support Quality Improvements for Lung Cancer Care | PR Newswire | 5/31/2019

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, MD ; Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, IL ; Mayo Clinic Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

National Comprehensive Cancer Network Working with Health Officials in Bolivia to Improve Cancer Care | PR Newswire | 4/24/2019

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

Ruth Bader Ginsburg

U.S. Justice Ginsburg makes first appearance since latest cancer scare | Yahoo News | 8/26/2019

Liberal U.S. Supreme Court Justice Ruth Bader Ginsburg appeared alert and in good spirits on Monday as she made her first public appearance since completing a three-week course of radiation therapy to treat pancreatic … was identified following a biopsy performed on July 31 at Memorial Sloan Kettering Cancer Center in New York. A court statement said the tumor was “treated definitively” and that there was no evidence of disease …

Michael J. Hennessy

OncLive® Announces Steering Committee for First-Ever OncLive® Global Expo | Business Wire | 4/29/2019

… pressing issues and selecting experienced and relevant faculty are two important parts of making the OncLive® Global Expo great,” said Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of OncLive®. “We have … Ola Landgren, M.D., Ph.D. , professor of medicine; chief, myeloma service; Memorial Sloan Kettering Cancer Center. Reshma Mahtani, D.O. , associate professor of medicine, director of community outreach, Sylvester Cancer Center, University of Miami Miller School of …

Sean Mackay

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer | PR Newswire | 12/14/2017

… therapies. “IsoPlexis is excited to play a role in groundbreaking research that can improve future cancer therapeutics for patients,” said Sean Mackay , IsoPlexis CEO and Co-Founder. “Like our other core technologies, the Iso-Omix … level, IsoPlexis’ original scientific leaders from Yale , Caltech, UCLA , and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures …

UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments | PR Newswire | 12/14/2017

… therapies. “IsoPlexis is excited to play a role in groundbreaking research that can improve future cancer therapeutics for patients,” said Sean Mackay , IsoPlexis CEO and Co-Founder. “Like our other core technologies, the Iso-Omix … level, IsoPlexis’ original scientific leaders from Yale , Caltech, UCLA , and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures …

Bill Clinton

U.S. Justice Ginsburg makes first appearance since latest cancer scare | Yahoo News | 8/26/2019

… that Ginsburg had undergone radiation therapy after a malignant tumor was identified following a biopsy performed on July 31 at Memorial Sloan Kettering Cancer Center in New York. A court statement said the tumor was … pancreas is 27.1% Ginsburg, appointed in 1993 by Democratic President Bill Clinton, had two cancerous nodules in her left lung removed last December. She was previously treated for pancreatic cancer in 2009 and colon cancer …

Robert W. Carlson

NCCN Advances Cancer Research and Oncology Career Development with Young Investigator Awards, Poster Presentations, and Fellows Program | PR Newswire | 5/8/2019

… to our poster presenters and fellows, NCCN recognizes our important role in preparing for the oncology practices of tomorrow,” said Robert W. Carlson , MD, Chief Executive Officer, NCCN . “Past Young Investigator Awardees have gone on … Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering Cancer Center, New York, NY ; Moffitt Cancer Center, Tampa, FL ; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

National Comprehensive Cancer Network Working with Health Officials in Bolivia to Improve Cancer Care | PR Newswire | 4/24/2019

… guidelines in Bolivia; now they will be even more accessible and appropriate for optimizing treatment practices across the country,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Working with local experts allows us to … Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove …

David Hansen

MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy | PR Newswire | 12/20/2017

… pharmacokinetics. Dr. Eileen O’Reilly , Associate Director of the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician, member at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College, is … from this study in the first quarter of 2018,” commented David Hansen , MabVax’s President and Chief Executive Officer . For additional information about the Phase 1 MVT-5873 clinical trial, please visit clinicaltrials.gov , and reference Identifier …

Sunil Agarwal

Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma | Business Wire | 12/11/2017

… data, particularly at dose level two, as these are patients with a poor prognosis who need better treatment options,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “These data support a potential best … leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an …

Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL | Business Wire | 12/10/2017

… defined composition of JCAR017 supports a potential best-in-class clinical profile and helps to unlock key translational insights,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “These insights will help guide our … leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an …

Donald Trump

David Koch: Billionaire Republican donor dies aged 79 - BBC News | 8/23/2019

Donald Trump over his immigration policy and tariffs. ‘Blood and money’: The story of the Koch brothers In 2018 Koch stepped down from Koch Industries - which refines crude oil, produces fertiliser, and manufactures household products - citing his declining health. He had been a philanthropist to the arts, especially ballet, and donated to New York’s Lincoln Center and Memorial Sloan Kettering Cancer Center hospital. He ran for vice-president as a …

UPDATE 1-U.S. Justice Ginsburg treated for pancreatic cancer | Yahoo News | 8/23/2019

… An abnormality was first detected in July, and the tumor was identified following a biopsy performed on July 31 at Memorial Sloan Kettering Cancer Center in New York. “She canceled her annual summer visit to … four liberal justices, were unable to continue serving, Republican President Donald Trump could replace her with a conservative, further shifting the court to the right. Trump has added two justices since becoming president in January …

Dominique Costantini

OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors | Business Wire | 1/4/2018

… a very promising market with a strong medical need and no available treatments for these patients in immunological escape,” said Dominique Costantini, CEO and Director of OSE Immunotherapeutics. “ We are delighted to welcome Gérard Tardy … alpha chain of IL-7R - Under a research collaboration with Memorial Sloan Kettering Cancer Center, New York. In auto-immune diseases and transplantation: FR104 , CD28-antagonist in immunotherapy - Phase 1 trial completed – For the treatment …

OSE Immunotherapeutics to Present at Biotech Showcase™ 2018 Conference | Business Wire | 1/4/2018

NANTES, France- Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that Dominique Costantini, CEO, will present an overview of the Company’s business and will be available to participate in one-on … alpha chain of IL-7R - Under a research collaboration with Memorial Sloan Kettering Cancer Center, New York. In auto-immune diseases and transplantation: FR104 , CD28-antagonist in immunotherapy - Phase 1 trial completed – For the treatment …